<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>2038</number>
    <updateDate>2023-01-11T13:36:00Z</updateDate>
    <updateDateIncludingText>2023-01-11T13:36:00Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <type>HR</type>
    <introducedDate>2017-04-06</introducedDate>
    <congress>115</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 163, Number 60 (Thursday, April 6, 2017)]From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. LARSON of Connecticut:H.R. 2038.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, Clause 1 and Article I, Section 9,Clause 7[Page H2791]</pre>]]></constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Referred to</name>
                <date>2017-04-07T14:50:44Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2017-04-06T13:12:45Z</date>
          </item>
        </activities>
      </item>
      <item>
        <systemCode>hswm00</systemCode>
        <name>Ways and Means Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2017-04-06T13:12:50Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Budgeting for Opioid Addiction Treatment Act</title>
        <congress>115</congress>
        <number>523</number>
        <type>S</type>
        <latestAction>
          <actionDate>2017-03-02</actionDate>
          <text>Read twice and referred to the Committee on Finance.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Identical bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2017-04-07</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2017-04-06</actionDate>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hswm00</systemCode>
            <name>Ways and Means Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2017-04-06</actionDate>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100-A</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2017-04-06</actionDate>
        <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2017-04-06</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2017-04-06</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>L000557</bioguideId>
        <fullName>Rep. Larson, John B. [D-CT-1]</fullName>
        <firstName>JOHN</firstName>
        <lastName>LARSON</lastName>
        <party>D</party>
        <state>CT</state>
        <middleName>B.</middleName>
        <district>1</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>B000574</bioguideId>
        <fullName>Rep. Blumenauer, Earl [D-OR-3]</fullName>
        <firstName>EARL</firstName>
        <lastName>BLUMENAUER</lastName>
        <party>D</party>
        <state>OR</state>
        <district>3</district>
        <sponsorshipDate>2017-05-22</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>R000577</bioguideId>
        <fullName>Rep. Ryan, Tim [D-OH-13]</fullName>
        <firstName>TIM</firstName>
        <lastName>RYAN</lastName>
        <party>D</party>
        <state>OH</state>
        <district>13</district>
        <sponsorshipDate>2017-07-13</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>K000389</bioguideId>
        <fullName>Rep. Khanna, Ro [D-CA-17]</fullName>
        <firstName>Ro</firstName>
        <lastName>Khanna</lastName>
        <party>D</party>
        <state>CA</state>
        <district>17</district>
        <sponsorshipDate>2018-04-10</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Cancer</name>
        </item>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Drug trafficking and controlled substances</name>
        </item>
        <item>
          <name>Drug, alcohol, tobacco use</name>
        </item>
        <item>
          <name>Health care coverage and access</name>
        </item>
        <item>
          <name>Health programs administration and funding</name>
        </item>
        <item>
          <name>Health promotion and preventive care</name>
        </item>
        <item>
          <name>Long-term, rehabilitative, and terminal care</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
        <item>
          <name>Sales and excise taxes</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2017-04-06</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2017-04-18T18:40:17Z</updateDate>
        <text><![CDATA[ <p><b>Budgeting for Opioid Addiction Treatment Act </b></p> <p>This bill amends the Internal Revenue Code, with respect to excise taxes on manufacturers, to impose a one cent per milligram fee on the sale of active opioids by the manufacturer, producer, or importer. The fee excludes prescription drugs used exclusively for the treatment of opioid addiction as part of a medically assisted treatment effort. </p> <p>The Department of Health and Human Services (HHS) must establish a program to provide rebates or discounts to cancer and hospice patients to ensure that they do not pay the fee. </p> <p>The bill amends the Public Health Service Act to require any increase in federal revenues from the fee after rebates and discounts are subtracted to be distributed to states under the Substance Abuse Prevention and Treatment Block Grant program. The states must use the funds exclusively for substance abuse (including opioid abuse) efforts in the states, including: (1) specified treatment programs, and (2) the recruitment and training of substance use disorder professionals to work in rural and medically underserved communities.</p> <p>HHS must report to Congress on the impact of this bill on the retail cost of opioids and patient access to opioid medication, the effectiveness of the discount or rebate for cancer and hospice patients, how the funds are being used to improve substance abuse treatment efforts, and suggestions for improving access to opioids for cancer and hospice patients and substance abuse treatment efforts. </p>]]></text>
      </summary>
    </summaries>
    <title>Budgeting for Opioid Addiction Treatment Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Budgeting for Opioid Addiction Treatment Act</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Internal Revenue Code of 1986 to establish a stewardship fee on the production and importation of opioid pain relievers, and for other purposes.</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Budgeting for Opioid Addiction Treatment Act</title>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2017-04-06T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-115hr2038ih/xml/BILLS-115hr2038ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2017-04-07</actionDate>
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
